CL2025000366A1 - Composiciones y metodos para el tratamiento de presicion del cancer - Google Patents
Composiciones y metodos para el tratamiento de presicion del cancerInfo
- Publication number
- CL2025000366A1 CL2025000366A1 CL2025000366A CL2025000366A CL2025000366A1 CL 2025000366 A1 CL2025000366 A1 CL 2025000366A1 CL 2025000366 A CL2025000366 A CL 2025000366A CL 2025000366 A CL2025000366 A CL 2025000366A CL 2025000366 A1 CL2025000366 A1 CL 2025000366A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- cancer
- methods
- precision treatment
- precision
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Primary Health Care (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Data Mining & Analysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Databases & Information Systems (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263396104P | 2022-08-08 | 2022-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2025000366A1 true CL2025000366A1 (es) | 2025-07-25 |
Family
ID=89852341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025000366A CL2025000366A1 (es) | 2022-08-08 | 2025-02-07 | Composiciones y metodos para el tratamiento de presicion del cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250387362A1 (https=) |
| EP (1) | EP4568663A1 (https=) |
| JP (1) | JP2025526644A (https=) |
| KR (1) | KR20250046322A (https=) |
| CN (1) | CN119947713A (https=) |
| AU (1) | AU2022474010A1 (https=) |
| CA (1) | CA3264480A1 (https=) |
| CL (1) | CL2025000366A1 (https=) |
| IL (1) | IL318887A (https=) |
| MX (1) | MX2025001546A (https=) |
| WO (1) | WO2024035425A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025217275A2 (en) * | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2026054617A1 (ko) * | 2024-09-09 | 2026-03-12 | 재단법인 아산사회복지재단 | 신장암 환자에서 방사선 치료 반응성을 예측하기 위한 유전자 패널 |
| CN119220612A (zh) * | 2024-11-29 | 2024-12-31 | 云南省肿瘤医院(昆明医科大学第三附属医院) | 一种增强肺部实体肿瘤趋化和抑瘤效果的car-t细胞构建方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2563797A1 (en) * | 2004-04-22 | 2005-11-10 | The University Of Utah | Kits and reagents for use in diagnosis and prognosis of genomic disorders |
| US10624869B2 (en) * | 2017-05-08 | 2020-04-21 | Stanislaw R. Burzynski | Methods for the treatment of recurrent glioblastoma (RGBM) |
-
2022
- 2022-12-02 KR KR1020257007699A patent/KR20250046322A/ko active Pending
- 2022-12-02 WO PCT/US2022/051695 patent/WO2024035425A1/en not_active Ceased
- 2022-12-02 CN CN202280100425.2A patent/CN119947713A/zh active Pending
- 2022-12-02 EP EP22955178.3A patent/EP4568663A1/en active Pending
- 2022-12-02 AU AU2022474010A patent/AU2022474010A1/en active Pending
- 2022-12-02 US US19/102,393 patent/US20250387362A1/en active Pending
- 2022-12-02 CA CA3264480A patent/CA3264480A1/en active Pending
- 2022-12-02 JP JP2025507205A patent/JP2025526644A/ja active Pending
- 2022-12-02 IL IL318887A patent/IL318887A/en unknown
-
2025
- 2025-02-06 MX MX2025001546A patent/MX2025001546A/es unknown
- 2025-02-07 CL CL2025000366A patent/CL2025000366A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022474010A1 (en) | 2025-02-20 |
| CA3264480A1 (en) | 2024-02-15 |
| IL318887A (en) | 2025-04-01 |
| EP4568663A1 (en) | 2025-06-18 |
| JP2025526644A (ja) | 2025-08-15 |
| US20250387362A1 (en) | 2025-12-25 |
| CN119947713A (zh) | 2025-05-06 |
| MX2025001546A (es) | 2025-04-02 |
| WO2024035425A1 (en) | 2024-02-15 |
| KR20250046322A (ko) | 2025-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025000366A1 (es) | Composiciones y metodos para el tratamiento de presicion del cancer | |
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| CO2021000151A2 (es) | Inhibidores de pd-1/pd-l1 | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
| MX2020012261A (es) | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. | |
| ECSP19042682A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| CL2023003965A1 (es) | Inhibidores cdk2. | |
| CL2021000175A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| CO2020015923A2 (es) | Antagonista de gremlin-1 para la prevención y tratamiento del cáncer | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CL2025002554A1 (es) | Compuestos tricíclicos inhibidores de parp1 y uso para tratar cáncer. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| CL2022000522A1 (es) | Lurbinectedina en el tratamiento del mesotelioma maligno. | |
| CR20230323A (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
| MX2018006531A (es) | Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. | |
| BR112022012867A2 (pt) | Tratamento de câncer com inibidores de cdk12/13 | |
| MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| PE20201349A1 (es) | Moduladores de la expresion de ezh2 | |
| MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
| MX2018015056A (es) | Composicion y aparato para el tratamiento de la alopecia inducida por quimioterapia. | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| MX2022011845A (es) | Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. |